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Detection and Quantification of Protein
Biomarkers from Fewer than 10 Cells*
Saju Nettikadan‡§, Korinna Radke‡, James Johnson¶, Juntao Xu‡, Michael Lynch‡,
Curtis Mosher‡, and Eric Henderson‡
The use of antibody microarrays continues to grow rapidly
due to the recent advances in proteomics and automation
and the opportunity this combination creates for high
throughput multiplexed analysis of protein biomarkers.
However, a primary limitation of this technology is the lack
of PCR-like amplification methods for proteins. Therefore,
to realize the full potential of array-based protein biomarker
screening it is necessary to construct assays that can de-
tect and quantify protein biomarkers with very high sensi-
tivity, in the femtomolar range, and from limited sample
quantities. We describe here the construction of ultrami-
croarrays, combining the advantages of microarraying in-
cluding multiplexing capabilities, higher throughput, and
cost savings with the ability to screen very small sample
volumes. Antibody ultramicroarrays for the detection of in-
terleukin-6 and prostate-specific antigen (PSA), a widely
used biomarker for prostate cancer screening, were con-
structed. These ultramicroarrays were found to have a high
specificity and sensitivity with detection levels using puri-
fied proteins in the attomole range. Using these ultrami-
croarrays, we were able to detect PSA secreted from 100
LNCaP cells in 3 h and from just four LNCaP cells in 24 h.
Cellular PSA could also be detected from the lysate of an
average of just six cells. This strategy should enable pro-
teomic analysis of materials that are available in very limited
quantities such as those collected by laser capture micro-
dissection, neonatal biopsy microspecimens, and forensic
samples. Molecular & Cellular Proteomics 5:895–901,
2006.
The development of novel and improved proteomic tech-
nologies in recent years has resulted in major efforts toward
the discovery of new protein biomarkers. This has resulted in
a rapid increase in the list of potential clinically relevant bi-
omarkers some of which have become useful in diagnostics,
prognostics, and therapeutics (1).
It is unlikely that individual biomarkers will be sufficiently
sensitive and reliable to serve as robust indicators of a dis-
ease state (2). Therefore, a concerted effort is ongoing to
develop methods for discovering and quantifying expression
profiles of ensembles of protein biomarkers that as a group
provide robust diagnostic information. Many currently known
biomarkers are found only in relatively low concentrations in
very complex mixtures (3). Hence a successful strategy to
detect these biomarkers has to provide reasonably high
throughput as well as high sensitivity and the capacity for
quantification.
Protein microarraying is a powerful strategy for multiplexed
analysis of gene expression, development of diagnostic pro-
cedures, and discovery of new pharmacologically active
agents (4, 5). Protein microarrays have distinct advantages
over traditional macroscopic methods of using less sample
volumes and increased number of analytes simultaneously
detected. These advantages translate to reduced reagent
costs, faster kinetics, higher throughput, and potentially im-
proved sensitivity.
Typically creation of protein arrays involves deposition of
suitable capture molecules, such as specific antibodies, in an
array format on an appropriate substrate. Each spot of the
array consists of capture antibodies against a single antigen.
The antigens are captured specifically onto these domains
and detected by a variety of techniques including direct la-
beling of the antigens and using a secondary antibody in a
sandwich assay (4, 6). Several different signal generation
schemes are used in antibody microarray applications includ-
ing fluorescently labeled secondary/tertiary antibodies (7),
staining of biotinylated antibodies with streptavidin conju-
gated with fluorescent or enzymatic tags (8, 9), rolling circle
amplification (10), and resonance light scattering by gold-
coated particles (11).
Contact printers and other arraying devices are used to
deposit nanoliter quantities of proteins in spatial arrays with
domain sizes typically ranging from 100 to 300 m in diam-
eter. Several studies have demonstrated the application of
protein microarraying technology in studying the proteins
from serum (12), cell culture (13), tissue (14), and culture
medium (10).
Further miniaturization of the capture domains, with individ-
ual domains much smaller than conventional microarrays,
offers many distinct advantages including higher array den-
sity, increased sensitivity by analyte harvesting, improved
binding kinetics, smaller reaction volumes, potentially re-
duced reaction times, and reduced amounts of analyte and
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ligand reagents (15, 16). Ekins et al. (15) demonstrated that an
assay that uses smaller capture domains and lower sample
volumes is more sensitive than one that uses larger capture
domains and larger sample volumes. This is particularly rele-
vant in the context of non-amplifiable protein biomarkers that
are available only in very small quantities (e.g. laser capture
microdissected materials, neonatal samples, and forensics
specimens). Importantly further miniaturization of surface-im-
mobilized protein microarrays creates new opportunities for
micro- and nanobiosensor development toward the goal of
proteomic analysis at the single cell level.
In this report we describe the use of protein “ultramicroar-
rays,” defined as arrays with spots sizes in the 1–20-m-
diameter range and occupying 1⁄100–1⁄10,000 of the surface area
of a conventional (100-m-diameter) microarray spot (17).
Ultramicroarrays represents an optimal level of bioarray min-
iaturization because they contain a sufficient number of mol-
ecules to provide a statistically robust signal while also pro-
viding the benefits of miniaturization described above.
Moreover ultramicroarrays permit analysis of protein profiles
from extremely limited sample volumes. Finally ultramicroar-
rays can be readily visualized in a standard fluorescence
system for readout and are also compatible with novel read-
out systems (e.g. atomic force microscopy).
We used prostate-specific antigen (PSA)1 and interleukin-6
(IL-6) as a model system. Serum PSA measurement has be-
come the most commonly used laboratory test for cancer (18).
PSA is a 33-kDa androgen-regulated serine protease and
member of the tissue kallikrein family of proteases (19). It is
produced by epithelial cells in human prostate glands and
secreted directly into the prostatic ductal system (20). PSA is
a major protein in the seminal fluid with a concentration of
0.5–2.0 mg/ml (21). Pleiotropic cytokine, IL-6, is a 21–30-kDa
glycoprotein that has been implicated in the androgen-inde-
pendent activation of androgen receptor (22, 23). It has also
been reported that the serum levels of IL-6 are elevated in
patients with prostate cancer (24). The serum levels of IL-6
may also be a significant bioprognostic factor in prostate
cancer (25).
Ultramicroarrays were constructed using capture antibod-
ies against IL-6 and PSA on an amine-reactive surface. These
ultramicroarrays were shown to capture their cognate antigen
specifically and with high sensitivity. Each of the antigens
could be detected in the picogram/milliliter range from puri-
fied proteins using only 1 l of the sample. This translates to
a detection sensitivity of femtogram quantities of proteins.
Furthermore using these ultramicroarrays, we were able to
detect PSA secreted from 100 LNCaP cells in 3 h and from
just four LNCaP cells in 24 h. Cellular PSA could also be
detected from the lysate of an average of just six cells.
EXPERIMENTAL PROCEDURES
Substrates—Silicon wafers patterned by reactive ion etching and
diced into 4-mm squares (chips) were used as substrates. The chips
were ultrasonically cleaned in water and absolute ethanol and sputter
coated with 5 nm of chromium and 10 nm of gold using a dual gun, ion
beam sputterer operating at 4 mA and 7 keV (South Bay Technologies).
The gold-coated, patterned substrates were immediately immersed in a
freshly prepared solution of prolinker B (Proteogen) (26) in chloroform
and incubated for 1 h to form an amine-reactive surface. The surfaces
were sequentially washed in chloroform and acetone, blown dry using a
stream of dry nitrogen, and stored in a nitrogen atmosphere.
Antigens and Antibodies—Mouse anti-PSA and goat anti-PSA
(Fitzgerald Industries) were used as the PSA capture antibody and
detection antibody, respectively. Rat anti-IL-6 (R&D Systems) and bi-
otinylated anti-IL-6 (eBioscience) were used as the IL-6 capture and
detection antibodies, respectively. Purified PSA was purchased from
Fitzgerald Industries, and recombinant IL-6 was purchased from R&D
Systems. Texas Red-labeled donkey anti-goat IgG (Jackson Immu-
noresearch Laboratories, Inc.) and Alexa Fluor 594-labeled streptavi-
din (Molecular Probes) were used as the secondary antibodies to
generate the fluorescence signal. Alexa 488-labeled rabbit anti-rat
IgG (Molecular Probes) was used to tag the capture antibodies.
Construction of Arrays—Ultramicroarrays were constructed using
an instrument we have developed called the NanoArrayerTM (27). The
NanoArrayer system includes microfabricated “print cartridges” (sur-
face patterning tools (SPTsTM)) and uses precise motion and environ-
mental control to transfer attoliter to femtoliter volumes of materials
from a reservoir on the SPT onto a surface (28).
The protein to be deposited was mixed 1:1 in a spotting buffer
(20% glycerol and 0.2 mg/ml n-octyl glucoside), and 1 l of this
mixture was placed onto a glass coverslip. Microfabricated SPTs
were treated by exposure to ultraviolet light and ozone in a TipCleaner
(BioForce Nanosciences, Inc.) for 30 min to render the device surface
hydrophilic. The SPT and the coverslip containing the protein droplet
were mounted into the NanoArrayer stage, and the distal end of the
SPT cantilever was immersed into the protein droplet, thereby loading
the SPT. The protein solution that spontaneously wicks into the
hydrophilic channel in the SPT is sufficient for the construction of
several hundred ultramicroscale domains. The SPT loaded with the
protein was then brought in contact with the surface to be arrayed
under constant force feedback and defined environmental conditions.
A relative humidity of 50% and temperature of 25 °C were used as
the standard conditions for antibody depositions in this study. The
dimensions of the deposited protein domains are determined by the
geometry of the distal end of the SPT; the duration, angle, and force
of contact of the SPT with the substrate; the chemical nature of the
substrate; and the humidity levels at the deposition surface. In this
report we optimized conditions for antibody deposition to create
antibody domains of 5–8 m. The deposition time for each spot
was less than 100 ms. This resulted in a 25-spot array being con-
structed in less than 25 s, including the translation time.
Standard Assay—The chips with the protein capture arrays were
incubated overnight at 70% humidity at room temperature and then
blocked with 1 ViriBlock solution (BioForce Nanosciences Inc.) at
room temperature for 30 min on a rocker. The chips were rinsed in
PBST (1 PBS, 0.2% Tween 80) and incubated with 1 l of antigen
(PSA or IL-6) at room temperature for 1 h in a humid environment. The
chips were washed in PBST two times for 5 min each and incubated
with the detection antibody (diluted 1:1,000 in PBST) for 1 h at room
temperature. The chips were washed in PBST two times (5 min each)
and tagged with Alexa Fluor 594-labeled streptavidin or Texas Red
anti-goat IgG (diluted 1:1,000 in PBST) and Alexa 488 anti-rat IgG
(diluted 1:1,000 in PBST). The surfaces were then washed three times
in PBST and examined by fluorescence microscopy.
1 The abbreviations used are: PSA, prostate-specific antigen; IL-6,
interleukin-6; SPT, surface patterning tool; a.u., arbitrary units.
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Data Acquisition—A Nikon TE 2000U inverted microscope
equipped with a 40 oil objective and filter sets for Cy2TM (Alexa
488TM) and Texas Red (Alexa 594TM) dyes were used for fluorescence
imaging. Images were captured using a cooled charge-couple device
digital camera with 1.3-megapixel resolution.
Cell Culture—LNCaP cells (ATCC CRL 1740) were propagated in
T-flasks containing complete medium (RPMI 1640 medium with 2 mM
L-glutamine adjusted to contain 1.5 g/liter sodium bicarbonate, 4.5
g/liter glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate, 90%;
and fetal bovine serum, 10%). Flasks were incubated at 37 °C in an
atmosphere of 95% air and 5% CO2. Medium replacements were at
2-day intervals. At 70–80% confluency, cells were trypsinized using
0.25% trypsin, 0.53 mM EDTA, pH 7.3 (Sigma). Released cells were
triturated using a 10-ml pipette and collected by centrifugation. Cells
were counted using improved Neubauer chambers and seeded at
10–12  103 cells/cm2 in 25-cm2 T-flasks. When cells reached 50%
confluency and existed mostly as individuals rather than clumps they
were again released from the substratum using trypsin-EDTA and
washed twice with complete medium and collected by centrifugation
(500  g for 3 min). Cells from one 25-cm2 T-flask were suspended in
4 ml of complete medium, and aggregates were allowed to settle from
the liquid column. The suspension containing mostly individual cells
was collected, and cell numbers were again determined. The con-
centration of cells was adjusted with complete medium to 5.26  105
cells/ml (2,000 cells/3.8 l).
Secreted PSA—Nine serial 2-fold dilutions of cells were made in
complete medium. Dilutions were carried to an average of four cells/
well. 3.8 l were seeded in 10 replicate wells of a 1,536-well plate
(Bellco) along with control medium in wells and a like number of
control non-PSA-producing reptilian cells. Medium and cells were
incubated for 24 h. Medium from each well for each cell type and
serial dilution was collected (3 l) and pooled to obtain a statistical
average for the number of cells in each well. The pooled, collected
medium was stored at 80 °C until assayed.
LNCaP cells prepared from 50% confluent T-flasks as above were
diluted so that each 3.8 l plated into a well of a 96-well plate
contained 100 cells at time 0. Medium above the attached cells (3 l)
from 10 identical wells was collected at the indicated times and frozen
at 80 °C until assayed for PSA.
Cellular PSA—LNCaP cells prepared from 50% confluent T-flasks
as above were adjusted with complete medium to 2,000 cells/50 l,
and nine serial 2-fold dilutions in complete medium were prepared.
Aliquots of 50 l from each dilution were added to 500-l microcen-
trifuge tubes (in triplicate), and the tubes were spun at 4,000 rpm for
4 min in a fixed angle rotor of a microcentrifuge. Medium was carefully
and totally removed from each tube using a blunt needle Hamilton
syringe. The cells were then lysed by three cycles of freezing and
thawing. The cellular debris were removed by centrifugation, and the
supernatant was collected and assayed for PSA.
Statistical Calculations—Each experiment was repeated three
times or more with at least five arrays for each attempt. Each data
point was the statistical average of minimally 15 different data sets.
The net fluorescence intensity (raw minus background intensity) of the
arrayed spots was obtained using Array Pro Analyzer software (Media
Cybernetics). Statistical calculations were carried out using Microsoft
Excel, and the results were graphed using Sigma Plot (SPSS Inc.).
RESULTS
In this study, capture antibodies were deposited in ultrami-
crodomains and immobilized using an amine-reactive chem-
istry. The captured antigens were detected using standard
sandwich assays and immunofluorescence microscopy. The
ability to directly image, rather than scan, ultraminiaturized
arrays makes data collection rapid and provides automatic
internal control with respect to instrumentation variability. The
experimental design is illustrated in Fig. 1.
Mouse anti-PSA ultramicroarrays were constructed adja-
cent to rat anti-IL-6 ultramicroarrays (both arrays were 3  6
with 15-m pitch; spot size  5–8-m) on amine-reactive
silicon surfaces. Alexa 488-conjugated anti-rat IgG, which is
known to cross-react with mouse IgG, was used to evaluate
the presence of the capture antibody on the chips (Fig. 2,
panels A and D). The fluorescent images clearly demonstrate
that the capture antibodies were bound to the chip only at
expected locales. In one instance a chip so constructed was
incubated with PSA, washed, and incubated with a goat anti-
PSA detection antibody to complete the antibody-target-an-
tibody sandwich. A Texas Red-conjugated anti-goat IgG was
used to generate a fluorescence signal from the detection
antibody and demonstrate that the arrayed capture antibody
was functional and had captured PSA (Fig. 2, panel B). The
fluorescence signals from both the Alexa 488 and Texas Red
dyes were restricted to the antibody-arrayed domains, and
there was a one-to-one correlation between the locations of
the two dyes.
Molecular specificity and multiplexing capability of the ul-
tramicroarrays used in this study were demonstrated by ar-
raying capture antibodies against PSA and mouse IL-6 on the
FIG. 1. Illustration of the experi-
mental system used in this study.
Mouse anti-PSA and goat anti-PSA
were used as the PSA capture antibody
and detection antibody, respectively.
Rat anti-IL-6 and biotinylated anti-IL-6
were used as the IL-6 capture and de-
tection antibodies, respectively. Texas
Red-labeled donkey anti-goat and Al-
exa Fluor 594-labeled streptavidin were
used as the secondary antibodies to
generate the fluorescence signal. Alexa
488-labeled rabbit anti-rat IgG was
used to tag the capture antibodies.
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same chip. As described above, the arrayed capture antibod-
ies were labeled with Alexa 488-conjugated anti-rat antibody
to demonstrate that they were immobilized at the expected
locations. The multiplexed arrays were incubated with either
purified PSA or purified recombinant IL-6 followed by com-
pletion of the antibody sandwich and fluorescence micros-
copy. Comparing the fluorescence data presented in Fig. 2,
panels B and D, illustrates that only the arrayed PSA and IL-6
antibodies captured the cognate proteins with virtually no
cross-talk within the limits of detection. Again there was a
one-to-one correspondence between the location of the cap-
ture antibody and the IL-6-specific fluorescence signal (Fig. 2,
panels C and F).
To evaluate the detection sensitivity of anti-PSA ultrami-
croarrays multiple PSA capture chips were constructed with
at least five arrays on each chip. These chips were incubated
with 1 l each of 10-fold serial dilutions of PSA. At least three
chips were incubated with each concentration of PSA. The net
fluorescence intensity (raw minus background intensity) of the
arrayed spots was obtained. Statistical calculations were car-
ried out, and the results were plotted. Each data point on the
graph was the statistical average of at least 15 different data
sets. The results presented in Fig. 3 indicate that anti-PSA
ultramicroarrays are capable of detecting PSA at a level of
10 pg/ml from only 1 l of the sample corresponding to
sensitivity at the attomole level.
To evaluate anti-PSA ultramicroarrays in a biological sys-
tem we used the well characterized cell culture model for
prostate cancer, LNCaP, which constitutively produces PSA.
Ten replicate 2-fold serial dilutions, starting at 2,000 cells/
well, were incubated for 24 h. The supernatants from each
serial dilution were pooled and stored at 80 °C. A small
volume of the pooled medium (3 l) was mixed with an equal
volume of PBST buffer and incubated on PSA capture chips
at room temperature for 1 h in a humid environment. The
chips were treated and evaluated as described under “Exper-
imental Procedures.” Each analysis was repeated at least
three times for each medium pool. The data presented (Fig. 4,
inset) compare the fluorescence intensities of the signal ob-
tained from the supernatant of 250 cells and that from four
cells. The net intensity over the range of dilutions used is
plotted in Fig. 4. These results show that PSA could be readily
detected from the supernatant of LNCaP cells. More impor-
tantly, a reliable signal was obtainable from the PSA secreted
by just four cells in 24 h.
To further evaluate the anti-PSA ultramicroarrays in a bio-
logical system, LNCaP cells were grown in a 1,536-well plate
with 100 cells in each well. The cells were incubated for
varying periods of time, and the supernatant was collected at
time points starting at 1 h to 24 h postincubation. The super-
natant was collected from at least five wells at each time
point, pooled, and mixed with an equal volume of PBST
buffer. A small volume of the pooled medium (3 l) was mixed
with an equal volume of PBST buffer and incubated on PSA
capture chips at room temperature for 1 h in a humid envi-
ronment. The chips were treated and evaluated as described
under “Experimental Procedures.” The net intensity of the
fluorescence signal over the indicated course of time is pre-
sented in Fig. 5. The data presented in Fig. 5, inset, compare
the fluorescence intensity of the signal obtained from the
secreted PSA by 100 LNCaP cells in 2 h and that in 23 h.
FIG. 2. Ultramicroscale immunofluorescent antibody capture
assay. Panels A and D show the deposition domains containing
capture antibodies for PSA and IL-6, visualized with an Alexa 488
(green)-coupled antibody. Panels B and E show specific capture of
PSA and IL-6, visualized with an Alexa 594 (red)-coupled detection
antibody. Panels C and F show the overlap of panels A and B and
panels D and E, respectively, to illustrate the one-to-one correspond-
ence between the capture antibody and the specific signal. Scale bar,
15 m.
FIG. 3. PSA detection sensitivity. 10-fold serial dilutions of PSA
were captured using chips with ultramicroarrays of PSA capture
antibodies. The fluorescent image was collected using the same
camera settings for each of the PSA concentrations, and the net
intensity (raw minus background) of the spots was obtained. The
mean net intensity for each concentration from three different chips
(125 spots/chip) was plotted. The higher limit is the result of photo-
sensor saturation under fixed conditions and does not represent the
ultimate upper detection limit of the system.
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These results show that PSA secreted by 100 cells could be
detected in the growth medium in less than 3 h.
In an effort to detect and quantify the cellular PSA levels,
LNCaP cells were harvested and diluted such that there were
2,000 cells/50 l. Nine 2-fold serial dilutions of the cells were
carried out and collected by centrifugation. Extra precautions
were taken to ensure that all of the secreted PSA was re-
moved by sequential washing of the cells before lysis. The
cells were lysed, and the supernatant was used to assay for
the presence of PSA. The data presented in Fig. 6, inset,
compare the fluorescence intensity of the signal obtained
from the cellular PSA from just two cells to that from 67 cells.
The intensity of the fluorescence signal over the number of
cells is presented in Fig. 6. The results demonstrate that the
cellular PSA from just six cells can be easily detected using
ultramicroarrays and a standard sandwich fluorescence as-
say. This level of sensitivity is unprecedented in the microar-
ray capture assays with fluorescence readout.
DISCUSSION
This study demonstrates the utility of ultramicroscale pro-
tein capture arrays for the detection and quantification of
protein biomarkers. Ultramicroarrays, i.e. arrays with domains
less than 20 m in diameter, were constructed using instru-
mentation and methodologies developed and previously de-
scribed by our research group (17, 28). This report presents
the first study demonstrating the significant advantages of
using ultramicroarrays in protein detection. Haab et al. (4)
arrayed 115 distinct antibodies and demonstrated that they
could detect antigens with a sensitivity of 1 ng/ml. A similar
study showed that cancer antigens could be detected at a
concentration of 5 ng/ml (13). Detection of epidermal growth
factor receptor and Her2 in a microarray format was achieved
at 1 ng/ml levels using a sandwich assay and was increased
to 0.1 ng/ml levels by direct labeling methods (7). Standard
sandwich immunofluorescence assay was used to detect 75
different cytokines at a concentration of 1 ng/ml in a microar-
ray format. Because this level of sensitivity was not sufficient
to detect physiologically relevant levels of cytokines, Schweit-
zer et al. (10) used rolling circle amplification to increase the
sensitivity to the order of 1–100 pg/ml. We have demonstrated
that PSA and IL-6 can be detected in the range of 10 pg/ml,
levels previously unattainable by other arraying technologies
using sandwich assays. We show that protein ultramicroar-
rays can be multiplexed and that they are capable of mean-
ingful detection of a cancer protein biomarker, PSA, from the
FIG. 4. PSA detection from a model cell culture system. 2-fold
serial dilutions of LNCaP cells were grown in 1,536-well plates, and
the supernatant was collected after 24 h. The supernatant was as-
sayed for PSA, and the relationship between net fluorescence signal
intensity and number of cells was plotted. Each point is the average
of at least three trials. The inset shows the raw fluorescence data from
250 (left) and four (right) cells.
FIG. 5. PSA detection from LNCaP cell as a function of time.
LNCaP cells were cultured in 1,536-well plates with 100 cells/well for
the indicated times. The supernatant was collected and assayed for
PSA. The net fluorescence signal intensity was plotted as a function
of time. The inset shows the raw fluorescence intensity at 2 h (left) and
23 h (right).
FIG. 6. Detection of cellular PSA. A serial dilution of LNCaP cells
was lysed, and the cellular PSA was assayed. The net fluorescence
signal intensity was plotted as a function of the cell number. The inset
shows the raw fluorescence data from two (left) and 67 (right) cells.
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supernatant of just four LNCaP cells.
One of the advantages of using ultramicroarrays is the high
density of the arrays, and thereby the large numbers of dif-
ferent capture domains, that can be constructed in a small
surface area. This enables the direct analysis of very small
sample volumes without having to dilute the sample and
thereby losing sensitivity. The 1–6-l volumes used in this
study were a vast volumetric excess in comparison to the
spatial requirements of ultramicroarrays, which are compati-
ble with submicroliter volumes. Another advantage of ultrami-
croscale capture domains is a reduction in the depletion of
analyte from the samples; this translates to enhanced reaction
kinetics.
The apparent limited dynamic range (Figs. 3, 5, and 6) is
due to saturation of the camera system used in this study. A
fixed exposure time was used for all samples to permit direct
comparison of fluorescence data. This resulted in charge-
coupled device saturation at high PSA concentrations. Use of
shorter exposure times or a more sophisticated light capturing
system would mitigate this apparent saturation and reveal the
true dynamic range of the system. A key feature of ultrami-
croarrays is that the molecular population of antibodies is on
the order of several hundred thousand molecules in a 5-m-
diameter spot. This was calculated based on the dimension of
an IgG to be 14.5  8.5  4 nm (29, 30) and an optimal
packing of IgG molecules. Therefore a 5-m spot will create
the opportunity for at least 3–4 logs of dynamic range while
retaining the advantages of ultraminiaturization. This consid-
eration is critical when evaluating single molecule approaches
to diagnostic testing.
Protein capture ultramicroarrays such as those demon-
strated here enable the detection and analysis of protein
biomarkers from extremely small samples. This capability pro-
vides a new pathway to the realization of opportunities in
many areas including protein biomarker analysis of laser cap-
ture microdissected, neonatal, and forensics microspeci-
mens. Protein capture ultramicroarrays are, in fact, a signifi-
cant advance toward the detection of protein biomarkers from
single cells.
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